ArticleBioscience reports2018
Analysis of miRNA signature differentially expressed in exosomes from adriamycin-resistant and parental human breast cancer cells.
Article in Bioscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Exosome-Mediated miRNA Delivery Restores Early Differentiation and Survival Programs in DGCR8-Deficient Mouse Embryonic Stem Cells.International journal of molecular sciences · 2026Article
- Meta graphical lasso: uncovering hidden interactions among latent mechanisms.Scientific reports · 2024Article
- Drug resistance in breast cancer is based on the mechanism of exocrine non-coding RNA.Discover oncology · 2024Review
- Extracellular Vesicles in Breast Cancer: From Biology and Function to Clinical Diagnosis and Therapeutic Management.International journal of molecular sciences · 2023Review
- miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.Cancers · 2023Article
- Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles.Respiratory research · 2023Article
- Exosomal miRNAs as novel avenues for breast cancer treatment.Frontiers in genetics · 2023Review
- Research progress of exosomes in drug resistance of breast cancer.Frontiers in bioengineering and biotechnology · 2023Review
- Alteration of miRNAs in Small Neuron-Derived Extracellular Vesicles of Alzheimer's Disease Patients and the Effect of Extracellular Vesicles on Microglial Immune Responses.Journal of molecular neuroscience : MN · 2022Article
- Exosomal microRNAs: Pleiotropic Impacts on Breast Cancer Metastasis and Their Clinical Perspectives.Biology · 2021Review
- Tumor-Derived Exosomal Non-Coding RNAs: The Emerging Mechanisms and Potential Clinical Applications in Breast Cancer.Frontiers in oncology · 2021Review
- Exosomes and breast cancer drug resistance.Cell death & disease · 2020Review
- Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.Journal of cellular and molecular medicine · 2020Article
- Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer.Bioscience reports · 2020Article
- Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- The Role of Exosomal MicroRNAs in the Tumor Microenvironment of Breast Cancer.International journal of molecular sciences · 2019Review
- The role of exosomal microRNAs; focus on clinical applications in breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major cause of failure in chemotherapy is drug resistance of cancer cells. Exosomes have been introduced to spread chemoresistance through delivering miRNAs. However, a systematic evaluation of the exosomal miRNA expression profiles responsible for chemoresistance is still lacking. In the present study, miRNA signature differentially expressed in exosomes derived from adriamycin-resistant (A/exo) and parental breast cancer cells (S/exo) were analyzed by microarray and the results were confirmed by PCR. A total of 309 miRNAs were increased and 66 miRNAs were decreased significantly in A/exo compared with S/exo. Specifically, 52 novel miRNAs with increased expression levels >16.0-fold in A/exo were identified. After prediction of target genes for 13 of 52 selected novel miRNAs, pathway analysis, gene ontology (GO) terms, and protein-protein interactions (PPIs) were constructed. The results implied that these selected exosomal miRNAs inhibited target genes involved in transcriptional misregulation in cancer, MAPK, and Wnt signaling pathways. Functional enrichment analysis demonstrated that the target genes were mainly responsible for protein phosphorylation, transcription regulation, molecular binding, and kinase activity. In summary, the current bioinformatics study of exosomal miRNAs may offer a new understanding into mechanisms of chemoresistance, which is helpful to find potential exosomal miRNAs to overcome drug insensitivity in future breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.